Company Overview

Matinas BioPharma Holdings, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing lipid nanocrystal (LNC) platform-based therapeutics and drug delivery technologies. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on improving the oral delivery, tolerability, and bioavailability of medicines that are traditionally difficult to administer. Matinas has historically concentrated on infectious diseases, oncology-supportive therapies, and lipid-based drug formulation technologies. Its primary value proposition centers on proprietary lipid nanocrystal delivery systems designed to enable oral administration of compounds that are otherwise delivered intravenously or associated with significant toxicity.

The company’s core business activities have revolved around advancing its proprietary LNC Platform Technology and related product candidates, including formulations involving amphotericin B and omega-3-derived therapeutics. Matinas was founded through the combination and evolution of predecessor biotechnology entities and became publicly traded on the NYSE American under the ticker MTNB. Over time, the company shifted from a broader lipid therapeutic focus toward platform-driven pharmaceutical delivery applications, seeking strategic collaborations with larger pharmaceutical companies interested in reformulating existing drugs using oral lipid nanocrystal technology.

Business Operations

Matinas conducts operations primarily through its proprietary LNC Platform development activities and associated clinical and preclinical programs. Historically, its lead product candidate was MAT2203, an oral formulation of amphotericin B intended for treatment of invasive fungal infections and other antifungal indications. The company has also evaluated lipid nanocrystal applications for small molecules, vaccines, nucleic acids, and other therapeutic payloads. Revenue generation has been limited and primarily associated with collaboration agreements, licensing arrangements, and research-related activities rather than commercialized product sales, consistent with its status as a clinical-stage biotechnology company.

Operations are centered largely in the United States, with research, corporate management, and development functions coordinated from its U.S. headquarters. Matinas has pursued strategic relationships with pharmaceutical and biotechnology partners to validate and expand use cases for the LNC Platform. Public disclosures, including SEC filings, have identified collaborations involving evaluation of oral delivery applications for complex therapeutics. The company does not maintain a broad commercial manufacturing infrastructure and instead relies on third-party contract research organizations and manufacturing partners for development and clinical supply activities.

Strategic Position & Investments

Matinas’ strategic direction has focused on leveraging the LNC Platform Technology as a drug delivery engine capable of improving oral bioavailability and reducing toxicity profiles of existing therapeutics. The company has emphasized platform licensing and collaborative development opportunities as a means of creating long-term value while limiting the capital intensity associated with full-scale commercialization. Management has repeatedly highlighted the potential applicability of the technology across antifungals, antivirals, oncology agents, and nucleic acid therapeutics.

A significant component of the company’s strategy involved continued development of MAT2203 and broader validation of the oral lipid nanocrystal platform through external partnerships. Publicly available information indicates the company has explored strategic alternatives, financing initiatives, and operational restructuring measures in response to capital market conditions and clinical development requirements. Matinas has also indicated interest in emerging sectors involving lipid-enabled delivery systems, including applications relevant to RNA and intracellular therapeutics. Data regarding long-term commercialization partnerships or large-scale acquisitions remains limited based on available public sources.

Geographic Footprint

Matinas BioPharma maintains its headquarters in Bedminster, New Jersey, and its operational footprint is primarily concentrated in the United States. Its clinical development and corporate activities have largely been U.S.-based, though the company’s research collaborations and potential market applications are international in scope. Clinical trial activity and regulatory engagement have included interaction with U.S. regulatory authorities, particularly the FDA.

The company’s strategic ambitions have targeted broader pharmaceutical markets across North America, Europe, and other global healthcare regions where improved oral drug delivery technologies may have commercial relevance. While Matinas does not maintain extensive international commercial operations or manufacturing networks, its platform technologies are intended for global pharmaceutical applications and partnership opportunities. Public filings do not indicate a substantial standalone international sales infrastructure.

Leadership & Governance

Matinas BioPharma has been led by executives with backgrounds in biotechnology development, pharmaceuticals, finance, and commercialization. The company’s governance structure follows the standard public-company model overseen by a board of directors and executive leadership team. Leadership communications in public filings and investor materials have consistently emphasized capital discipline, platform validation, strategic collaborations, and advancement of differentiated drug delivery technologies.

Key executives and leadership figures identified in recent public disclosures include:

• Jerome D. Jabbour – Chief Executive Officer
• Raphael G. Amit, Ph.D. – President and Chief Operating Officer
• Randall C. Younker – Chief Financial Officer
• Roopal Thakkar, M.D. – Former Chief Medical Officer
• Leonard M. Mazur – Chairman of the Board

The company’s leadership philosophy has generally centered on advancing proprietary lipid-based delivery technologies through strategic partnerships, disciplined clinical development, and targeted therapeutic applications with unmet medical needs. Information regarding certain executive roles and organizational changes may vary across reporting periods due to restructuring and leadership transitions disclosed in public filings.